|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,989.90 INR | +0.67% |
|
+1.43% | +15.71% |
| 07-21 | South Africa regulator reviews 12 generic semaglutide applications | RE |
| 07-15 | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| Market Cap | 4,774B 49.85B 43.8B 40.88B 37.52B 70.24B 71.97B 485B 190B 2,363B 187B 183B 8,167B | P/E 2027 * |
36.5x | P/E 2028 * | 30.9x |
|---|---|---|---|---|---|
| Enterprise Value | 4,511B 47.1B 41.38B 38.63B 35.45B 66.36B 68B 458B 179B 2,232B 177B 173B 7,717B | EV / Sales 2027 * |
6.89x | EV / Sales 2028 * | 6.09x |
| Free-Float |
44.39% | Yield 2027 * |
0.8% | Yield 2028 * | 0.89% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.67% | ||
| 1 week | +1.43% | ||
| Current month | +6.84% | ||
| 1 month | +6.82% | ||
| 3 months | +13.88% | ||
| 6 months | +23.55% | ||
| Current year | +15.71% |
| 1 week | 1,926.8 |  | 1,993 |
| 1 month | 1,859.4 | | 1,993 |
| Current year | 1,583.7 | | 1,993 |
| 1 year | 1,548 | | 1,993 |
| 3 years | 1,068.35 | | 1,993 |
| 5 years | 696.15 | | 1,993 |
| 10 years | 312 | | 1,993 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.67% | +1.43% | +16.90% | +74.77% | 49.64B | |
| +1.05% | +3.84% | +64.12% | +113.57% | 36.54B | |
| +2.06% | +2.92% | -6.22% | +25.17% | 12.22B | |
| +2.14% | -1.78% | +14.55% | +75.28% | 11.48B | |
| +1.05% | +1.16% | +31.33% | +131.86% | 9.04B | |
| +3.08% | +3.94% | +50.54% | -4.41% | 6.94B | |
| +0.17% | -0.68% | +11.96% | +33.49% | 6.74B | |
| +3.53% | +0.87% | +5.47% | +183.15% | 6.45B | |
| +0.61% | -6.24% | -32.70% | -1.66% | 5.42B | |
| +1.62% | -5.00% | +22.75% | +110.21% | 4.37B | |
| Average | +1.60% | -1.32% | +17.87% | +74.14% | 14.88B | |
| Weighted average by Cap. | +1.25% | +0.25% | +26.51% | +81.13% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.83B 6B 5.6B 5.14B 9.63B 9.86B 66.44B 25.98B 324B 25.65B 25.09B 1,119B | 730B 7.62B 6.69B 6.25B 5.73B 10.73B 11B 74.09B 28.98B 361B 28.6B 27.98B 1,248B |
| Net income | 132B 1.38B 1.21B 1.13B 1.04B 1.94B 1.99B 13.42B 5.25B 65.4B 5.18B 5.07B 226B | 156B 1.63B 1.43B 1.34B 1.23B 2.3B 2.35B 15.85B 6.2B 77.22B 6.12B 5.98B 267B |
| Net Debt | -263B -2.75B -2.42B -2.26B -2.07B -3.88B -3.97B -26.75B -10.46B -130B -10.33B -10.1B -451B | -329B -3.43B -3.02B -2.81B -2.58B -4.84B -4.95B -33.37B -13.05B -163B -12.88B -12.6B -562B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/07/26 | ₹1,989.90 | +0.67% | 2,682,295 |
| 28/07/26 | ₹1,976.70 | +0.15% | 4,579,529 |
| 27/07/26 | ₹1,973.70 | +1.68% | 5,414,380 |
| 24/07/26 | ₹1,941.10 | -0.66% | 1,578,929 |
| 23/07/26 | ₹1,954.00 | +0.57% | 2,057,288 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
